Page last updated: 2024-12-07

fluoroclebopride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fluoroclebopride: structure given in first source; a dopamine D1 and D2 receptor-based imaging agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127887
CHEMBL ID125237
MeSH IDM0222526

Synonyms (29)

Synonym
bdbm50042726
4-amino-5-chloro-n-[1-(4-fluoro-benzyl)-piperidin-4-yl]-2-methoxy-benzamide
fluoroclebopride
CHEMBL125237 ,
4-amino-5-chloro-n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-2-methoxybenzamide
154540-49-5
benzamide,4-amino-5-chloro-n-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-2-methoxy-
benzamide, 4-amino-5-chloro-n-(1-((4-fluorophenyl)methyl)-4-piperidinyl)-2-methoxy-
4-amino-5-chloro-n-(1-((4-fluorophenyl)methyl)-4-piperidinyl)-2-methoxybenzamide
DTXSID10165659
4-amino-5-chloro-n-(1-((4-fluorophenyl)methyl)-4-piperidinyl)-2-methox ybenzamide
n-{3-[2-({2,3-difluoro-4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl}amino)-8-quinazolinyl]phenyl}acrylamide
J-690204
AKOS026751480
EX-A1212
4-amino-5-chloro-n-(1-(4-fluorobenzyl)piperidin-4-yl)-2-methoxybenzamide
BCP17738
4-amino-5-chloro-n-[1-(4-fluorobenzyl)-4-piperidinyl]-2-methoxybenzamide
F17407
mfcd28163070
FT-0700218
CCG-357974
4-amino-5-chloro-n-(1-(4-fluorobenzyl)-4-piperidinyl)-2-methoxybenzamide
A14056
A883718
CS-0022984
HY-102089
4-amino-5-chloro-n-{1-[(4-fluorophenyl)methyl]piperidin-4-yl}-2-methoxybenzamide
EN300-20232979
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.28300.00020.667710.0000AID5288
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.28300.00010.601710.0000AID5288
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki1.30000.00000.929610.0000AID218816
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki1.30000.00000.970810.0000AID218816
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki1.30000.00000.937510.0000AID218816
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.28300.00020.590910.0000AID5288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID24231Partition coefficient (logP)1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography.
AID5288In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography.
AID218816In vitro binding affinity on alpha-2 receptor is inhibition of binding of [3H]- rauwolscine to rat cortex1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography.
AID65735Inhibition of [125I]- NCQ 298 binding to D2 receptor of rat striatal tissue1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (50.00)18.2507
2000's4 (40.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.87 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]